Tiba Biotech
June 17, 2025
Company Presentation
Immunology
153C
Tiba Biotech develops next generation RNA vaccines and therapeutics, with a focus on infectious diseases, cancer, and inflammation. Our proprietary RNABL platform overcomes the limitations of conventional LNP delivery, and is compatible with multiple modalities including messenger, self-amplifying, circular, and short interfering RNA. RNABL delivery chemistry is based on biodegradable ionizable molecules that exhibit superior safety, stability, and potency versus traditional lipid-based systems. This approach is highly flexible and customizable, enabling effective in vivo transfection by intramuscular, intranasal, intratumoral, and intravenous routes of administration. An ongoing BARDA FASTx project has established robust and safe delivery to the lung by systemic and inhaled administration, and the platform has been validated in grant-funded vaccine programs against H7N9 influenza (NIH) and Japanese Encephalitis Virus (CEPI).
Company HQ City:
Cambridge
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
Pandemic influenza vaccine
CEO
Karl Ruping
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
Strategic commercial partnership, immuno-oncology
What is your next catalyst (value inflection) update?
Jan 2026
Website
https://tiba.bio/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}